For a successful therapy of Candida infections –
the Adiclair®-productfamily

Adiclair is considered one of the most important base therapeutics to treat infections caused by Candida spp. Depending upon therapeutic needs, the active pharmaceutical ingredient nystatin can be used in a number of different dosage forms. These all exert just a topical effectiveness, resulting in very good clinical tolerance.

  • safe, well-established and effective therapy of Candida mycoses
  • very well-tolerated
  • no clinically relevant resistance So far, no clinically relevant resistance towards nystatin has been observed. This also applies for the treatment of Candida glabrata, where increased resistances have been seen more recently to the newer azole antimycotic drugs.
  • generally applicable to all age-groups
  • Nystatin, biological API for safe topical application Nystatin is practically not absorbed after topical application to the skin, the mucous membranes or after oral administration. Nystatin neither passes the placenta nor is a transfer into mother's milk to be expected. Accordingly, nystatin can also be used during pregnancy and lactation.

Adiclair pharmaceutical forms

  • Adiclair Film-coated tablets
  • Adiclair Suspension
  • Adiclair Nystatin Mouth Gel
  • Adiclair Ointment

Therapeutic indications for Adiclair

  • Mucocutaneous manifestations as e.g. oral thrush, diaper dermatitis
  • Symptomatic gastrointestinal manifestations and the detection of 105 or more yeast cells/g of stool, if applicable SAP positive and the exclusion of the most frequent diarrhea-producing pathogens (definition of the DGHM)
  • Recurrent extra-intestinal fungal infections with a suspected intestinal yeast reservoir

Adiclair Film-coated tablets international package insert to download
Adiclair Suspension international package insert to download
Adiclair Nystatin Mouth Gel international package insert to download
Adiclair Ointment international package insert to download